Application of withaferin A in preparation of medicine for treating fundus ischemic disease

A technology for ischemic diseases and medicines, applied in the field of pharmacy, can solve the problems that no one has reported or is not aware of the dual role of WithaferinA in anti-oxidative stress cell death and targeted anti-VEGF, and achieve clear and effective effects. The effect of clear mechanism and stable chemical structure
CN110151769BActive Publication Date: 2020-11-13闫喆一
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
闫喆一
Publication Date
2020-11-13

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses application of Withaferin A in preparing a drug for treating a fundus ischemic disease. Experiments show that the Withaferin A can inhibit the fundus ischemic disease from theperspective of pathogenesis through two mechanisms that 1, oxidative stress cell necrosis and apoptosis caused by ischemia are significantly reduced; 2, targeted inhibition of a vascular endothelial growth factor and a signaling pathway of a receptor (VEGF-VEGFR2) of the vascular endothelial growth factor is achieved, and the pathological microvascular hemorrhage leakage, abnormal blood vessel growth and other symptoms are ameliorated. The Withaferin A significantly relieves the symptoms of the fundus ischemic disease and inhibits the generation and development of the disease through the dualeffects of the two mechanisms. The Withaferin A as a small molecule targeting compound has a stable and safe chemical structure and can penetrate through a blood-eye barrier, therefore the WithaferinA has a broad application prospect in the fundus ischemic disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The invention belongs to the technical field of pharmacy, and specifically relates to the application of Withaferin A in the preparation of medicines for treating fundus ischemic diseases. Background technique

[0002] Retinal and choroidal ischemia and hypoxia are collectively referred to as ischemic fundus diseases, which are important causes of vision loss and loss, including: 1. Acute ischemia: ophthalmic artery occlusion, central retinal artery occlusion, branch retinal artery occlusion, ciliary Retinal artery occlusion, distant retinopathy, Purtscher-like retinopathy, etc.; 2. Chronic ischemia: central retinal vein occlusion, branch vein occlusion, diabetic retinopathy, ocular ischemic syndrome, Takayasu arteritis fundus lesions, premature infant retina lesions, age-related macular degeneration, etc. Chronic fundus ischemic disease can also lead to complications such as neovascular glaucoma and corneal neovascularization.

[0003] Retinal and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More